RLS Global presents positive results from the ChloraSolv01 study at the leading European Wound Management Conference, EWMA 2020
RLS Global is pleased to announce that an abstract has been reviewed by the EWMA Scientific Committee and accepted for Oral Presentation at the EWMA 2020 Virtual Conference. The abstract “ID no. 927” will be presented by Senior consultant, Associate professor Jan Apelqvist, Skåne University Hospital, Sweden.
The abstract presents a few key data from the clinical study ChloraSolv01. The Intention-to-treat (ITT) population consisted of 57 patients with a median age of 73 years. Inclusion criteria was all wounds below the knee. It was found that after only six treatments /debridements (last treatment) with ChloraSolv, 71,4% of the patients had ≥50% reduction of devitalized tissue. The study showed low pain score in general. The change of devitalized tissue from baseline to post debridement at visit 6 was -72,7%. At the same time, the wound size reduction was -30.9%.
An overall evaluation by the investigators/nurses showed that 68,9% of the responders agree that ChloraSolv debridement gel makes the debridement easier than previously used debriding treatments, whereas only 3,8% do not agree.
This investigation showed that debridement in conjunction with the use of ChloraSolv was well tolerated and efficient. Most of the investigators/nurses found that debridement was easier performed with ChloraSolv than treatments previously used.
“We are very pleased that the abstract with some key data from the ChloraSolv01 study was selected for oral presentation at EWMA”, says Karin Fischer – CEO RLS Global. “These events are excellent opportunities for us to further reach out with the successful results within the international scientific community. An important milestone for RLS Global”, concludes Karin Fischer.
To take part of the full abstract please use the link below:
Trading place and
RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: email@example.com. During the period 2012 - 2017, the company was listed on Aktietorget.
RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contract person, at 13-10-2020 10:30 CET.
Karin Fischer, CEO
Phone: +46 702 48 46 51
Mats Ahlenius, CTO
Phone: +46 707 41 03 39
About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv®, Perisolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: firstname.lastname@example.org. Read more at www.rls.global